Allergan Inks $51M Deal To End Direct Buyers' Restasis Suit
Allergan has struck a $51.2 million deal with buyers of dry-eye medication Restasis to end allegations that the pharma giant fought to keep a generic version of the medication off the...To view the full article, register now.
Already a subscriber? Click here to view full article